| Not Yet Recruiting | A Single-center Study of CM313 in Patients With Pemphigus NCT06904040 | Sichuan Provincial People's Hospital | N/A |
| Recruiting | Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus NCT05898308 | University Hospital, Rouen | Phase 4 |
| Recruiting | A Clinical Study of B007 in the Treatment of Pemphigus. NCT06454357 | Shanghai Jiaolian Drug Research and Development Co., Ltd | Phase 2 / Phase 3 |
| Unknown | Coagulation Activation in Patients With Pemphigus NCT06285435 | Assiut University | — |
| Completed | Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids NCT06654817 | Chao Ji | — |
| Unknown | Validation of 5-Point Investigator Global Assessments for Pemphigus NCT05534776 | Premier Specialists, Australia | — |
| Recruiting | ONO-4059 Study in Patients With Steroid-resistant Pemphigus NCT06696716 | Ono Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus NCT04400994 | The University of Hong Kong | Phase 2 |
| Terminated | A Study of PRN1008 in Patients With Pemphigus NCT03762265 | Principia Biopharma, a Sanofi Company | Phase 3 |
| Recruiting | FARD (RaDiCo Cohort) (RaDiCo-FARD) NCT05954416 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Terminated | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) NCT03075904 | Alexion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus NCT05284929 | Sechenov University | — |
| Terminated | Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris NCT02613910 | GlaxoSmithKline | Phase 3 |
| Completed | Identification of Vulnerability Factors in the Course of Pemphigus Patients NCT02237313 | University Hospital, Rouen | N/A |
| Unknown | Wound Dressings for Pemphigus and Pemphigoid NCT02365675 | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | N/A |
| Terminated | Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid NCT01559155 | Centre Hospitalier Universitaire de Nīmes | — |
| Unknown | Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemp NCT01974518 | Uprety Shraddha | Phase 3 |
| Completed | Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab NCT01299857 | University Hospital, Rouen | Phase 3 |
| Terminated | Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus NCT01313923 | University of California, Irvine | EARLY_Phase 1 |
| Unknown | Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex NCT01338103 | Rabin Medical Center | N/A |
| Completed | The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders NCT00960713 | University Hospital, Toulouse | — |
| Completed | Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus NCT00656656 | University of Luebeck | Phase 2 |
| Completed | Use of Infliximab for the Treatment of Pemphigus Vulgaris NCT00283712 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Effect of Anti CD20 in Pemphigus Desease NCT00213512 | University Hospital, Rouen | Phase 2 / Phase 3 |
| Terminated | Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders NCT00278642 | Richard Burt, MD | Phase 1 |
| Completed | European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus NCT00127764 | University Medical Center Groningen | Phase 2 / Phase 3 |
| Completed | Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus NCT00010413 | Johns Hopkins University | Phase 2 |